927TiP SKYSCRAPER-09: A phase II, randomised, double-blinded study of atezolizumab (Atezo) + tiragolumab (Tira) and atezo + placebo as first-line (1L) therapy for recurrent/metastatic (R/M) PD-L1+ squamous cell carcinoma of the head and neck (SCCHN)

E. Cohen, J. Fayette, K.J. Harrington, M.L. Johnson,H-F. Kao,S-H. Lee, L.F. Licitra, N. Ngamphaiboon, A. Psyrri, D.J. Wong, M. Afshari, K. Cvijovic, G.R. Goodman, K.M. Komatsubara, C. Matheny, T.Q. Pham, H. Tang,L. Wang, Y. Yan, M. Gillison

Annals of Oncology（2021）

引用 0|浏览0

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要